Dale Schenk
About Dale Schenk
Dale Schenk serves as the President and Chief Executive Officer of Prothena Corporation Plc, where he focuses on developing therapeutic agents for AL Amyloidosis. With a background in biotechnology and significant contributions to Alzheimer's and CNS diseases, he has a Ph.D. and has published extensive research in the field.
Current Role at Prothena Corporation
Dale Schenk serves as the President and Chief Executive Officer of Prothena Corporation Plc, a position he has held since 2012. Under his leadership, Prothena focuses on developing therapeutic agents for AL Amyloidosis and other neurodegenerative diseases. His extensive experience in the biotechnology sector has been instrumental in guiding the company's strategic direction and research initiatives.
Previous Experience at Elan
Before joining Prothena, Dale Schenk worked at Elan Corporation as Executive Vice President and Chief Scientific Officer from 2008 to 2012. During his tenure in Dublin, Ireland, he played a key role in the company's scientific strategy and contributed to the development of innovative therapies, including Tysabri®.
Education and Expertise
Dale Schenk earned a Bachelor of Arts in Biology from the University of California, San Diego, from 1975 to 1979. He continued his education at the same institution, obtaining a Doctor of Philosophy in Physiology and Pharmacology from 1979 to 1984. His academic background supports his expertise in immunochemistry, animal models, and the development of therapeutic agents.
Scientific Contributions and Research
Dale Schenk has made significant contributions to the field of neuroscience, particularly in Alzheimer's disease and Parkinson's disease. He has published research on synuclein immunization, monoclonal antibodies for amyloidosis, and amyloid imaging and therapy. His work has advanced the understanding of neurodegenerative diseases and has influenced both policy directions and scientific innovations.
Management Experience in Biotechnology
Dale Schenk possesses extensive experience in managing biotechnology start-ups and organizations. His leadership has been pivotal in shaping research agendas and fostering collaborations within the biotechnology community. He has also contributed to policy development in the non-profit and government sectors related to Alzheimer's and CNS diseases.